bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Employees - 75,
CEO - Ms. Maria Zannes J.D.,
Sector - Healthcare,
Country - US,
Market Cap - 10.92M
Altman ZScore(max is 10): -11.17, Piotroski Score(max is 10): 2, Working Capital: $57974, Total Assets: $6552014, Retained Earnings: $-50677413, EBIT: -8336614, Total Liabilities: $3430989, Revenue: $9367785
- Current Price $0.70 - Analyst Target Price $6.00| Ticker | BIAF |
| Index | - |
| Curent Price | 0.70 |
| Change | -21.22% |
| Market Cap | 10.92M |
| Average Volume | 9.58M |
| Income | -9.04M |
| Sales | 9.36M |
| Book Value/Share | 0.17 |
| Cash/Share | 0.07 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 57 |
| Moving Avg 20days | 75.70% |
| Moving Avg 50days | 21.71% |
| Moving Avg 200days | -48.16% |
| Shares Outstanding | 15.58M |
| Earnings Date | Mar 31 BMO |
| Inst. Ownership | 3.44% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 1.17 |
| Price/Book | 4.20 |
| Price/Cash | 9.84 |
| Price/FCF | - |
| Quick Ratio | 0.86 |
| Current Ratio | 0.87 |
| Debt/Equity | 0.58 |
| Return on Assets | -122.70% |
| Return on Equity | -242.44% |
| Return on Investment | -265.19% |
| Gross Margin | 29.62% |
| Ops Margin | -95.64% |
| Profit Margin | -96.56% |
| RSI | 58.28 |
| BETA(β) | 3.20 |
| From 52week Low | 191.64% |
| From 52week High | -77.83% |
| EPS | -0.74 |
| EPS next Year | -0.21 |
| EPS next Qtr | -0.16 |
| EPS this Year | 40.00% |
| EPS next 5 Year | - |
| EPS past 5 Year | -10.71% |
| Sales past 5 Year | 10579.42% |
| EPS Y/Y | 18.87% |
| Sales Y/Y | 269.68% |
| EPS Q/Q | 25.79% |
| Sales Q/Q | -0.26% |
| Sales Surprise | -8.93% |
| EPS Surprise | -35.71% |
| ATR(14) | 0.16 |
| Perf Week | 159.19% |
| Perf Month | 82.34% |
| Perf Quarter | -22.96% |
| Perf Year | -66.93% |
| Perf YTD | -22.96% |
| Target Price | 6.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer